株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

癌治療薬パイプラインにおけるエピジェネティック療法

Epigenetic Therapy in Oncology Drug Pipeline Update

発行 BioSeeker Group AB 商品コード 263208
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
癌治療薬パイプラインにおけるエピジェネティック療法 Epigenetic Therapy in Oncology Drug Pipeline Update
出版日: 2016年08月04日 ページ情報: 英文
概要

当レポートでは、エピジェネティック療法を標的とした癌治療薬の開発状況を個別に調査分析し、開発事業者および提携事業者、開発ステージ別の分類、標的の種類と分子機能、標的の位置特定、発現プロファイル、その他の適応症などをまとめ、概略下記の構成でお届けいたします。

調査内容

  • 開発事業者(58社)・提携事業者
  • 薬剤名および異名
    • 商標名
    • ジェネリック薬
    • コードネーム
  • 開発ステージの分類:癌治療薬において開発中のエピジェネティック療法65種・計233件の開発プロジェクト
    • 上市済み
    • 登録前
    • 第3相
    • 第2相
    • 第1相
    • 前臨床
    • データなし
    • 中断
    • 中止
  • 適応症
  • 標的:34種の標的・14の分子機能分類
    • クロマチン結合
    • 脱アセチル化酵素活性
    • DNA結合
    • DNAメチルトランスフェラーゼ活性
    • キナーゼ活性
    • 脂質キナーゼ活性
    • メチルトランスフェラーゼ
    • プロテインセリン/スレオニンキナーゼ活性
    • プロテインチロシンキナーゼ活性
    • 受容体活性
    • 転写調節因子活性
    • 膜貫通受容体プロテインチロシンキナーゼ活性
    • トランスポーター活性 など
  • 特定標的の細胞下のロケーション:9ヵ所
    • クラスリン被覆小胞
    • 細胞質
    • 小胞体
    • エンドソーム
    • 細胞外
    • ミトコンドリア
    • 核小体
    • 原形質膜

標的の発現プロファイル

  • 48種の正常組織
  • 20種の癌
  • 47種の細胞株
  • 一次血球の12サンプル

経路の照会

機序

化合物

薬剤プロファイル

  • 薬剤名
  • 治験担当医師およびパートナー
  • 標的および標的の分子機能
  • 標的の部位
  • 標的経路
  • 機序
  • 開発プロジェクト
  • 薬剤解説
  • 化合物データ
  • 特許データ
  • 分析
  • 第3相データ
  • 第2相データ
  • 第1相データ
  • 臨床前データ
  • ライセンシング情報

Drug Pipeline Updateソフトウェア・アプリケーションについて

システム要件

  • Operating system: Windows (2000/XP/Vista/7/8) for Mac Users the service is only available online
  • Browser Application (Internet Explorer, Firefox, Chrome, Safari)
  • Internet access (to access related internet resources)

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BSG17666

Epigenetic abnormalities are frequent events implicated in the development of many different types of tumors. The first epigenetic modification that was linked to cancer was methylation and to date there are several approved epigenetic drugs in oncology (eg, Azacitidine, Decitabine, Vorinostat, Romidepsin, Ruxolitinib).

Today a majority of drugs targets histone methylation and acetylation, also frequently dysregulated in cancer cells, in the form of inhibitors of histone acetyltransferases (HATs), histone deacetylases (HDACs), histone methyltransferases (HMTs) and histone demethylases (HDMs). In addition, there is a third major category of drug targets that contain bromodomains (eg, the BET family BRD2, 3, 4, and BRDt) that bind to histone acetylation regions of the genome and recruit certain proteins.

So far, epigenetic drugs have shown significant synergistic potential in combination with traditional chemotherapy drugs, and many combination trials are currently under way.

There are today 101 companies plus partners developing 129 epigenetic therapy drugs in 477 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 36 drugs. Epigenetic Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 57 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 55 out of the 56 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 18 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

How May Drug Pipeline Update Be of Use?

  • Show investors/board/management that you are right on top of drug development progress in your therapeutic area. * Find competitors, collaborations partners, M&A candidates etc. * Jump start competitive drug intelligence operations * Excellent starting point for world wide benchmarking * Compare portfolio and therapy focus with your peers * Speed up pro-active in-/out licensing strategy work * Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug. Drug Pipeline Update is delivered to you as a downloadable application, which requires no installation on your computer. Please read more about application features and system requirements below.

Table of Contents

Drug Pipeline Update at a Glance

Investigators

  • Includes more than 101 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.
  • Note: You are able to sort and find drugs according to companies and partners from drop-down menus in the application. You may also sort and find drugs according to country of companies.

Drug name & Synonyms

  • Lists commercial, generic and code names for drugs.

Developmental stage

  • This Drug Pipeline Update contains 129 epigenetic therapy drugs in development, which have a total of 477 developmental projects in cancer. In addition there are suspended and ceased drugs.
  • Pipeline Breakdown According to Number of Drugs
  • Marketed# 7
  • Pre-registration# 1
  • Phase III# 8
  • Phase II# 34
  • Phase I# 45
  • Preclinical# 54
  • No Data# 5
  • Suspended# 1
  • Ceased# 36
  • Note: You are able to sort and find drugs according to developmental stage from drop-down menu in the application.

Indications

  • Included epigenetic therapy drugs are also in development for 101 other indications, where of 87 are different cancer indications.
  • Note: You are able to find and sort drugs according to type of indication from drop-down menu in the application.

Targets

  • Mutations
  • All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers. To date 55 out of the 56 studied drug targets so far have been recorded with somatic mutations and the software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.
  • Biological Structures
  • The identity of available biological structures on 45 drug targets was retrieved from the RCSB Protein Databank for you to easily review the 1077 structures available today among drug targets.
  • Identified drugs are linked to more than 57 different targets, divided into 18 classifications of molecular function:
  • Catalytic activity
  • Chromatin binding
  • Deacetylase activity
  • Deaminase activity
  • DNA binding
  • DNA-methyltransferase activity
  • Kinase activity
  • Lipid kinase activity
  • Methyltransferase activity
  • Molecular function unknown
  • Protease inhibitor activity
  • Protein serine/threonine kinase activity
  • Protein-tyrosine kinase activity
  • Receptor activity
  • Receptor signaling complex scaffold activity
  • Transcription regulator activity
  • Transmembrane receptor protein tyrosine kinase activity
  • Transporter activity
  • Sub-Cellular Localization
  • Identified targets are categorized into 12 different primary and alternate sub-cellular localizations:
  • Clathrin-coated vesicle
  • Cytoplasm
  • Cytoskeleton
  • Endoplasmic reticulum
  • Endosome
  • Extracellular
  • Mitochondrial membrane
  • Mitochondrion
  • Nucleolus
  • Nucleus
  • Plasma membrane
  • Ribosome
  • Note: You are able to find and sort drugs according to target gene name, protein name, molecular function of target, target localization, presence of mutations and availability of biological structures of target from drop-down menus in the application.

Target Expression Profile

  • Direct links are provided from inside the application to 77 protein expression profiles of 53 drug targets in various human tissues and cancer types, cell lines and primary cells, including up to:
  • 48 different normal tissue types
  • 20 different types of cancer
  • 47 cell lines
  • 12 samples of primary blood cells

Pathway Referals

  • Identified targets have been cross referenced against their involvement in different cellular pathways, according to BioCarta, KEGG, NCI-Nature and NetPath.
  • BioCarta# 136 Pathways
  • KEGG# 114 Pathways
  • NCI-Nature# 181 Pathways
  • NetPath# 32 Pathways
  • Note: You are able to find and sort drugs according to targeted pathways from drop-down menus in the application.

Mechanism

  • In total there are different drug mechanism of action represented in this Drug Pipeline Update.
  • Note: You are able to find and sort drugs according to mechanism of action from drop-down menu in the application.

Compound

  • Identified drug compounds are described by:
  • Compound type, Chemical name, CAS Number and molecular weight
  • Note: You are able to sort and find drugs according to compound type from drop-down menu in the application.

Drug Profile

  • Progress analysis and review of drug development. A typical drug profile reports on, depending on stage of development and available information:
  • Drug Name & Synonyms
  • Presentation of drug name and synonyms

Principal Company & Partners

  • Presentation of principal company and partners

Target and Molecular Function of Target

  • Described target(s) is/are presented with:
  • Official Gene Symbol - Chromosome Location - Gene & Protein Name - Molecular Function

Target Localization

  • Described target(s) is/are presented with primary and alternate localizations.
  • Target Expression Profiles
  • Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to:
  • 48 different normal tissue types
  • 20 different types of cancer
  • 47 cell lines
  • 12 samples of primary blood cells

Mutation

  • All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers.
  • Biological Structures
  • The identity of available biological structures on drug targets was retrieved from the RCSB Protein Databank for you to easily review what available structures of drug targets exist.

Targeted Pathways

  • Described target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, NCI-Nature and NetPath.

Mechanism

  • Drug mechanism of action

Developmental Projects

  • Summary field of developmental projects for the drug, including indication, developmental stage and status.
  • Example:
  • Cancer, myeloma - Phase II Clinical Trial - Active
  • Cancer, prostate - Phase III Clinical Trial - Ceased

Drug Description

  • Short introduction to drug

Compound Data

  • Compound type, Chemical name, CAS Number and molecular weight

Patent Data

  • Available patent information related to the drug is presented here.

Fillings and Approvals

  • Approvals and submissions
  • Analyst comments
  • Deals & Licensing
  • Collaborations and deals
  • Availability for licensing

Phase IV Data

  • Available Phase IV development data, developmental history and scientific data.

Phase III Data

  • Available Phase III development data, developmental history and scientific data.

Phase II Data

  • Available Phase II development data, developmental history and scientific data.

Phase I Data

  • Available Phase I development data, developmental history and scientific data.

Phase 0 Data

  • Available Phase 0 development data, developmental history and scientific data.

Preclinical Data

  • Available preclinical development data, developmental history and scientific data.

Discovery Data

  • Available discovery development data, developmental history and scientific data.

Application Features

  • Search, Find and Filter Panel with Initial Result Presentation
  • With this panel you can define your selectivity in each drug search with up to 24 different drug specific parameters. Each parameter has multi-select options to them and can be used as either an inclusion parameter or exclusion parameter.
  • The initial result table is a dynamic sortable table which gives you a fast overview of found results and can be narrowed down further by your own additional keywords.
  • Direct linkage from inside the application to related internet resources
  • Drug data is linked to search engines like Google and PubMed
  • Drug target data is linked directly to BioCarta, Human Protein Atlas, KEGG, NCI-Nature, NetPath etc.
  • Direct links to company web pages of companies

Dynamic Report Generator

  • Our dynamic report generator lets you with ease and speed generate html reports directly in your web browser (Internet Explorer and FireFox), whether it is a single drug profile or an entire search you want have a report of.

System Requirements

  • Operating system: Windows (2000/XP/Vista/7/8) for Mac Users the service is only available online
  • Browser Application (Internet Explorer, Firefox, Chrome, Safari)
  • Internet access (to access related internet resources)
Back to Top